메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Singapore-Based Innovative Biomedical Start-Up Achieves 'S…

[ 메디채널 김갑성 기자 ] NMPA grants Syntellix product approval for the world's most important future market with more than 1.4 billion people Syntellix' product approval for China is the largest and most important success in the company's history; product approval in China was the company's most important strategic and operational goal Syntellix had previously already been granted the accelerated 'innovative pathway' by the NMPA due to the exceptional benefits of its products In total, product approvals for Syntellix products have accumulated to date in countries with more than 5.5 billion
- 김갑성 기자
- 2025-07-23 15:35
Landmark Trial Demonstrates Efficacy of Microcurrent Therap…

ZUG, Switzerland, July 23, 2025 -- Berlin Heals and the C-MIC II Investigators today announced the publication of the C-MIC II trial results in the European Journal of Heart Failure. The study, titled "Cardio-microcurrent Device Treatment for Heart Failure with Reduced Ejection Fraction: Results from the C-MIC II Open Label Randomized Controlled Trial," was previously presented as a Late-Breaking Clinical Trial (LBCT) at the 2025 ESC-HFA Congress in Belgrade. The findings mark a major advancement in the field of bioelectronic medicine for heart failure, highl
- 김갑성 기자
- 2025-07-23 15:00
Zylox-Tonbridge Issues Positive Profit Alert, Expects Over RMB 1…

HANGZHOU, China, July 23, 2025 -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, "Zylox-Tonbridge" or the "Company"), a leading medical device company in China's peripheral and neurovascular interventional market, today announced a positive profit alert for the six months ended June 30, 2025. Based on preliminary unaudited figures, the Company expects to record revenue of over RMB 480 million, representing a year-on-year increase of approximately 31.1%. Net profit is anticipated to exceed RMB 115 million, reflecting a robust growth of approximately 66.9% compare
- 김갑성 기자
- 2025-07-23 14:57
Samsung Biologics reports second quarter 2025 financial re…

Recorded Q2'25 consolidated revenue of KRW 1,289.9 billion Recorded Q2'25 consolidated operating profit of KRW 475.6 billion Solid momentum sustained through capacity ramp-up and stable project execution INCHEON, South Korea, July 23, 2025 -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025. "Our second quarter results demonstrate continued strong momentum across our business," said John Rim, CEO and Pr
- 김갑성 기자
- 2025-07-23 14:54
HIMSS APAC 2025: Malaysian Health Minister Visits GuidelineX Exh…

KUALA LUMPUR, Malaysia, July 22, 2025 -- Dr. Dzulkefly Ahmad, Minister of Health of Malaysia, visited the GuidelineX exhibition at HIMSS APAC 2025, where he engaged in comprehensive discussions on AI-powered clinical decision support systems (CDSS). The minister examined the practical applications of GuidelineX's technology, which has supported 61 million inpatient visits and facilitated 1.4 billion outpatient visits annually across China, representing 25% and 33% of the national patient visits to hospitals, respectively. Dr. Ahmad noted Malaysia's ongoing efforts in digital health and
- 김갑성 기자
- 2025-07-22 22:20
BostonGene Receives Frost & Sullivan's 2025 North American E…

BostonGene's comprehensive AI-powered platform integrates multiomics data to accelerate discovery, reduce development risk and advance precision oncology across all stages the R&D continuum SAN ANTONIO, July 22, 2025 -- Frost & Sullivan has named BostonGene the recipient of the 2025 North American Enabling Technology Leadership Award in recognition of the company's pioneering role in advancing precision oncology. BostonGene's clinically validated, AI-powered platform uses a multimodal approach to decode disease and uncover predictive biological signatures. BostonGene c
- 김갑성 기자
- 2025-07-22 22:00
LG AI Research Showcases 'EXAONE Ecosystem' at LG AI Talk…

[ 메디채널 김갑성 기자 ] Pioneering AI Transformation from Bio to Business Intelligence SEOUL, South Korea, July 22, 2025 -- LG AI Research hosted its "LG AI Talk Concert 2025" today at the LG Sciencepark Convergence Hall in Magok, Seoul, showcasing the evolution of its EXAONE ecosystem. The event highlighted the culmination of five years of AI development, featuring advanced AI models and services designed for real-world industrial applications. Woohyung Lim, Co-President of LG AI Research, outlined future plans, stating, "LG AI Research will secure global competitivene
- 김갑성 기자
- 2025-07-22 22:00
Kolmar Korea Launches Full Operation of 2nd US Factory, Es…

New 17,805㎡ facility completed in Pennsylvania with an annual production capacity of 300 million units Full ODM production capabilities in the US — from color cosmetics to skincare and suncare — mitigating tariff and supply chain risks 'MADE BY KOLMAR' world-class manufacturing technology localized to the US market OLYPHANT, Pa. and SEOUL, South Korea, July 22, 2025 -- Kolmar Korea has officially completed construction and begun full-scale operations of its second manufacturing facility in the United States, the world's largest cosmetics market. Located in Scott Townsh
- 김갑성 기자
- 2025-07-22 20:30
A novel oral treatment for Alzheimer's: Actinogen's pivotal tria…

All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem® vs. placebo for 36 weeks, followed by an open label extension of active Xanamem for up to 24 months SYDNEY, July 22, 2025 -- Actinogen Medical Limited (ASX: ACW) is encouraging individuals and their loved ones affected by Alzheimer's disease to take part in a groundbreaking clinical trial that could transform the way we treat this devastating condition. The trial is enrolling people diagnosed with mild to moderate Alzheimer's disease, offering them a chance
- 김갑성 기자
- 2025-07-22 20:00
Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise. Q2 2025 Highlights Q2 2025 unaudited group revenue of approximately $204 million, up 63% year-over-year. FY 2025 revenue guidance of $770 million to $800 million is reaffirmed. Gozellix® launched in the U.S. and commercial dose deliveries commenced. Gozel
- 김갑성 기자
- 2025-07-22 16:02

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 01시 40분